SIST2401

SIST2401 is a small molecule therapeutic candidate currently under development by Samik Pharmaceutical as a first generic for the treatment of hyperlipidemia. As a first generic, it is designed to be the first bioequivalent version of a reference listed drug to enter the market, typically following a successful patent challenge or upon the expiration of the original drug's patent exclusivity. The drug is currently in Phase 1 clinical development, where its safety, tolerability, and pharmacokinetic profile are being evaluated in healthy volunteers to establish bioequivalence with the reference product. SIST2401 is part of Samik Pharmaceutical's strategic focus on expanding its portfolio in the cardiovascular and metabolic disease areas.